Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors

Clinical Therapeutics

Volumn 18, Issue 3, 1996, Pages 521-527

  Gregor, Karl J ^a,b   Riley, Joy A ^a   Downing, Daniel K ^a  

^a PCS Health Systems Incorporated   (United States)

^b Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FLUOXETINE; HYPNOTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; DATA BASE; DEPRESSION; DRUG USE; ECONOMIC ASPECT; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; PRESCRIPTION; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 0029889411     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80034-8     Document Type: Article

References (5)

1. Tollefson GD. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB, eds. The Amerìcan Psychiatric Press Textbook of Psychopharmacology, First Edition. Washington, DC: American Psychiatric Press, Inc; 1995:161-182.
2. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17:786-790.
3. Navarro R, Valler WE, Spangler M. Antidepressant utilization in managed care: An evaluation of SSRI use in two HMO settings. Med Interface. 1995;8:114-123.
4. Data on file. PCS Health Systems, Inc, Scottsdale, Arizona, 1996.
5. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res. 1995;23: 395-412.